Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection

This study has been terminated.
(Inadequate accrual rate)
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: April 7, 2014
Last updated: August 18, 2015
Last verified: April 2015
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: July 2015
  Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)